The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure.
J. Shan
No relevant relationships to disclose
S. M. O'Brien
No relevant relationships to disclose
G. Garcia-Manero
No relevant relationships to disclose
S. Faderl
No relevant relationships to disclose
F. Ravandi
Honoraria - Eisai; Johnson & Johnson
Research Funding - Eisai
E. Jabbour
Honoraria - Bristol-Myers Squibb; Novartis
J. E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
H. Kantarjian
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer